Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity
Authors
Keywords
-
Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-30
DOI
10.1016/j.cytogfr.2022.06.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-Dose IL-2 Treatment Affords Protection against Subarachnoid Hemorrhage Injury by Expanding Peripheral Regulatory T Cells
- (2021) Guoping Dong et al. ACS Chemical Neuroscience
- IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
- (2021) Yuying Liu et al. NATURE IMMUNOLOGY
- An engineered IL-2 partial agonist promotes CD8+ T cell stemness
- (2021) Fei Mo et al. NATURE
- The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
- (2021) Shen Dong et al. JCI Insight
- Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus
- (2021) Pengcheng Zhou et al. PLoS Pathogens
- Low dose IL-2 for treating moderate to severe alopecia areata. A 52 weeks multicenter prospective placebo-controlled study assessing its impact on T regulatory cells and natural killer populations
- (2020) Florence Le Duff et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
- (2020) Miro E. Raeber et al. Science Translational Medicine
- Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis
- (2020) Laura Elisa Buitrago-Molina et al. JOURNAL OF AUTOIMMUNITY
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
- (2019) Jing He et al. ANNALS OF THE RHEUMATIC DISEASES
- Germinal center TFH cells: T(w)o be or not t(w)o be, IL-6 is the answer
- (2019) Pengcheng Zhou et al. Science Immunology
- Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells
- (2019) Amber Papillion et al. Science Immunology
- Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome
- (2018) Miao Miao et al. ANNALS OF THE RHEUMATIC DISEASES
- Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis
- (2018) Tiong Y. Lim et al. HEPATOLOGY
- IL-2 Inhibition of Th17 Generation Rather Than Induction of Treg Cells Is Impaired in Primary Sjögren’s Syndrome Patients
- (2018) Jing Luo et al. Frontiers in Immunology
- Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
- (2018) Michelle Rosenzwajg et al. ANNALS OF THE RHEUMATIC DISEASES
- Regulatory T cells in the treatment of disease
- (2018) Amir Sharabi et al. NATURE REVIEWS DRUG DISCOVERY
- IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression
- (2017) Nicolas Hipp et al. Nature Communications
- IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2
- (2017) Christoph Jandl et al. Nature Communications
- Testosterone Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation
- (2017) Jacqueline-Yvonne Cephus et al. Cell Reports
- Interleukin-2-Dependent Allergen-Specific Tissue-Resident Memory Cells Drive Asthma
- (2016) Brian D. Hondowicz et al. IMMUNITY
- EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells
- (2016) Jianhua Li et al. NATURE
- Metabolic maintenance of cell asymmetry following division in activated T lymphocytes
- (2016) Katherine C. Verbist et al. NATURE
- An essential role for the IL-2 receptor in Treg cell function
- (2016) Takatoshi Chinen et al. NATURE IMMUNOLOGY
- IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity
- (2016) Yoichiro Ohne et al. NATURE IMMUNOLOGY
- Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
- (2016) Jing He et al. NATURE MEDICINE
- Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study
- (2016) Laurence Fardet et al. PLOS MEDICINE
- Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
- (2015) Caroline von Spee-Mayer et al. ANNALS OF THE RHEUMATIC DISEASES
- Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
- (2015) Jens Y Humrich et al. ANNALS OF THE RHEUMATIC DISEASES
- Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
- (2015) Aixin Yu et al. DIABETES
- The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells
- (2015) John P. Ray et al. IMMUNITY
- Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
- (2015) Michelle Rosenzwajg et al. JOURNAL OF AUTOIMMUNITY
- Bcl-6 directly represses the gene program of the glycolysis pathway
- (2014) Kenneth J Oestreich et al. NATURE IMMUNOLOGY
- High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
- (2014) Janice P Dutcher et al. Journal for ImmunoTherapy of Cancer
- IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts
- (2013) L. J. Berglund et al. BLOOD
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
- (2013) Erin E. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease
- (2013) K.-i. Matsuoka et al. Science Translational Medicine
- Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
- (2013) Agnès Hartemann et al. Lancet Diabetes & Endocrinology
- Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell Differentiation
- (2012) André Ballesteros-Tato et al. IMMUNITY
- The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study
- (2011) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages
- (2011) Wei Liao et al. NATURE IMMUNOLOGY
- Foxp3+ follicular regulatory T cells control the germinal center response
- (2011) Michelle A Linterman et al. NATURE MEDICINE
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-2 Costimulation Enables Statin-Mediated Activation of Human NK Cells, Preferentially through a Mechanism Involving CD56+ Dendritic Cells
- (2010) G. Gruenbacher et al. CANCER RESEARCH
- Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo
- (2010) Vandana Kalia et al. IMMUNITY
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
- (2010) Yenkel Grinberg-Bleyer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Infections as triggers and complications of systemic lupus erythematosus
- (2008) A Doria et al. AUTOIMMUNITY REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now